Severe thrombocytopenia possibly related to readministration of eptifibatide.
Thrombocytopenia following eptifibatide therapy is a rare event, and acute severe thrombocytopenia following readministration has not been reported. We describe a case of acute severe thrombocytopenia following reexposure to eptifibatide during percutaneous coronary intervention. We continue to monitor platelet counts at 2-4 hr and 16-24 hr following administration of any glycoprotein IIb/IIIa inhibitor. Cathet Cardiovasc Intervent 2001;54:63-67.
Paradiso-Hardy
F L
FL
Department of Pharmacy, Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario, Canada. fran.paradiso-hardy@swchsc.on.ca
Madan
M
M
Radhakrishnan
S
S
Hurden
S
S
Cohen
E A
EA
D000328:Adult; D015906:Angioplasty, Balloon, Coronary; D003327:Coronary Disease / Q000097:blood / Q000628:therapy*; D000077542:Eptifibatide; D006801:Humans; D008297:Male; D010455:Peptides / Q000008:administration & dosage* / Q000009:adverse effects* / Q000097:blood; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects* / Q000097:blood; D010976:Platelet Count; D013921:Thrombocytopenia / Q000097:blood / Q000139:chemically induced*
D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D000077542:Eptifibatide